日批在线视频_内射毛片内射国产夫妻_亚洲三级小视频_在线观看亚洲大片短视频_女性向h片资源在线观看_亚洲最大网

Global EditionASIA 中文雙語Fran?ais
China

'China solution' targets high-risk breast cancer

By Zhou Wenting in Shanghai | China Daily | Updated: 2025-12-26 00:00
Share
Share - WeChat

A large-scale study by Chinese researchers offers a new treatment path for patients with the most aggressive form of breast cancer, providing what experts call a "China solution" for a disease that has long been difficult to treat.

The trial focused on triple-negative breast cancer, often considered the most dangerous version of the disease because it lacks the three common "hooks" — or receptors — that most modern drugs use to identify and kill cancer cells. Because these hooks are missing, doctors have struggled to find targeted treatments that work for every patient, often leaving chemotherapy as the only option.

The study, conducted by researchers at Fudan University Shanghai Cancer Center, found that adding the chemotherapy drug carboplatin to the standard treatment plan significantly improved outcomes. Patients in the experimental group reached a three-year survival rate of 92.3 percent without recurrence, a notable improvement over the 85.8 percent seen in the control group.

The findings were published on Tuesday in the medical journal BMJ. The researchers named the study "Citrine", after the yellow gemstone that symbolizes hope. Triple-negative breast cancer accounts for about 25 percent of all breast cancer cases and is known for its high risk of recurrence, which is when the cancer comes back, or metastasis, which is when the cancer spreads to other organs within five years of the initial diagnosis.

Lead researcher Shao Zhimin, a chief expert at the cancer center, said the study aims to move away from a "one-size-fits-all" approach. He noted that even with standard follow-up care after surgery, many patients still experience the cancer returning or spreading to distant parts of the body. Shao said the goal is to identify high-risk patients early and provide personalized care.

The team began this clinical research in 2021, focusing on patients categorized as high risk. This includes people whose cancer had already spread to their lymph nodes — small glands that help the body filter waste and fight infection — or patients whose tumor cells were growing and dividing at an unusually fast rate.

In the trial, which involved more than 800 participants, the researchers found that the addition of carboplatin reduced the relative risk of the cancer returning by 36 percent. For those in the experimental group, the three-year overall survival rate reached an impressive 98 percent.

Shao explained that the extra medication provided a crucial buffer during the period immediately following surgery, which is the most vulnerable time for these patients.

Wang Zhonghua, the deputy head of the hospital's breast surgery department, added that the trial showed no new or unexpected safety risks, which provides a solid foundation for doctors to begin using this treatment method more widely in clinics.

Today's Top News

Editor's picks

Most Viewed

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 欧美日韩在线视频免费观看 | 神马一区二区三区 | 精品欧美一区二区三区 | 日韩欧美中文字幕在线播放 | 国产乱国产乱 | 久热免费在线 | 欧美自拍偷拍一区 | 一区二区三区视频在线免费观看 | 天天国产视频 | 黄色在线观看国产 | 色综合久久88色综合天天 | 欧美综合一区二区三区 | 亚洲免费国产 | 国产精品一区二区免费看 | 国产一级二级三级在线观看 | 亚洲区一区二区 | 久久免费大片 | 中文字幕欧美一区 | 欧美精品免费一区二区三区 | 超污网站在线观看 | 亚洲精品aaa | 色av吧| 国产精品婷婷午夜在线观看 | 在线观看视频亚洲 | 日韩精品中文字幕一区二区 | 免费观看黄色一级片 | 黄色网久久| 国产精品aaa | 欧美成人精品一区二区三区在线看 | 欧美一区精品 | 久久久久婷婷 | 免费毛片av | 日韩在线视频观看免费 | 二区免费视频 | 青青草手机视频在线观看 | 亚洲图片欧美色图 | 国产永久免费观看 | 亚洲成人少妇 | 中出中文字幕 | 一区二区三区四区在线播放 | 成人观看 |